Table 4.
Summary of baseline characteristics and plasma biomarkers in dementia with Lewy bodies and corticobasal syndrome groups according to CSF amyloid (A+/–) status
| DLB | CBS | |||||
|---|---|---|---|---|---|---|
| A+ (n = 17) | A− (n = 31) | p value | A+ (n = 14) | A− (n = 15) | p value | |
| Age, years | 73.4 (6.3) | 73.6 (7.1) | 0.937 | 71.4 (8.0) | 71.3 (6.6) | 0.973 |
| Sex (female) | 7 (38.9%) | 7 (22.6%) | 0.326 | 7 (50.0%) | 11 (73.3%) | 0.263 |
| MMSE, /30 | 19.2 (6.3) | 25.1 (3.5) | < 0.001 | 23.6 (6.8) | 25.1 (4.1) | 0.829 |
| NfL (pg/mL) | 29.3 (17.1–29.3) | 20.4 (14.6–35.5) | 0.129 | 24.0 (16.4–53.1) | 27.9 (21.6–53.3) | 0.477 |
| p-tau181 (pg/mL) | 2.5 (1.9–3.5) | 1 (0.7–1.8) | < 0.001 | 2.0 (1.0–3.2) | 1.0 (0.7–1.3) | 0.004 |
| GFAP (pg/mL) | 485.1 (380.9–705.3) | 242.7 (211.1–417.2) | < 0.001 | 380.7 (325.3–642.9) | 225.5 (178.8–302.9) | 0.007 |
Age is expressed as mean (SD), while biomarker data are presented as median (IQR)